MEDICAMEN BIOTECH LTD.-$

Medicamen Biotech Ltd has announced the closure of its trading window for all designated persons and their immediate relatives. The window will be shut from July 01, 2026, and will reopen 48 hours after the declaration of the un-audited financial results for the quarter ended June 30, 2026. This measure is in compliance with the company's code of conduct for regulating trading by insiders. All concerned individuals have been advised against trading in the company's securities during this period. The date for the board meeting to approve these financial results will be communicated separately.

The Board of Directors, at its meeting on May 27, 2026, recommended a final dividend of ₹1.00 per equity share (face value ₹10.00) for the financial year ended March 31, 2026, subject to shareholder approval at the upcoming Annual General Meeting. The Board also approved the audited consolidated and standalone financial results for the quarter and financial year ended March 31, 2026, which received an unmodified opinion from M/s Rai Qimat & Associates, the statutory auditors. Additionally, M/s SPB & Co was appointed as the cost auditor and M/s Cheena & Associates as the internal auditor for the financial year 2026-27.

Medicamen Biotech Ltd. announced audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board approved a final dividend of ₹1.00 per equity share of face value ₹10.00, subject to shareholder approval. They also approved the appointment of M/s SPB & Co as cost auditor and M/s Cheena & Associates as internal auditor for FY 2026-27. The audit reports issued by M/s Rai Qimat & Associates on the financial statements contained unmodified opinions. The board meeting concluded on May 27, 2026.

Medicamen Biotech Ltd has scheduled a Board of Directors meeting on May 27, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026. The board will also consider the recommendation of a final dividend on equity shares for the financial year 2025-26, and the appointment of Cost and Internal Auditors for the financial year 2026-27. The trading window has been closed since April 1, 2026, and will open 48 hours after the financial results are declared.

Medicamen Biotech Ltd. has clarified that an event currently being reflected on the NSDL portal under the company's login credentials is incorrect and inadvertent. The company has taken up the matter with NSDL for necessary verification and rectification. They confirm that there is no material event or information requiring disclosure from their end.

Medicamen Biotech Ltd. has announced the closure of the trading window for all Directors, Designated Persons, and Connected Persons under the Code from April 01, 2026. The closure will last till 48 hours after the declaration of Audited Financial Results for the quarter and year ended on March 31, 2026. This decision is in accordance with the provisions of the Code of Conduct to Regulate, Monitor and Report trading by Designated Persons and their immediate relatives. All Directors, Designated Persons, and Connected Persons under the Code have been advised not to trade in the securities of the Company during this period.

Medicamen Biotech Ltd. has received a cautionary letter from the National Stock Exchange of India Ltd. (NSE) on 27th January, 2026, regarding observations reported by the Secretarial Auditor in the Annual Secretarial Compliance Report (ASCR) for the financial year ended 31st March, 2025. The Company has been advised to be careful in future to avoid recurrence of such lapses and adhere to the requirements of the applicable provisions/regulations as per the Listing Regulations. There is no impact on the financials, operations, or other activities of the Company.

Medicamen Biotech Ltd has issued a corrigendum regarding the completion of term of Independent Directorship of Mr Harish Pande and Mr Arun Kumar. Due to a clerical/typographical error, the date of retirement was inadvertently mentioned as February 13, 2026 in the earlier intimation. The correct date of retirement is February 26, 2026. Consequently, Mr. Harish Pande and Mr. Arun Kumar ceased to be an Independent Director of the Company with effect from February 26, 2026.

Medicamen Biotech Ltd has announced that Mr. Harish Pande and Mr. Arun Kumar have completed their term as Independent Directors of the Company. The Board of Directors and the Management have expressed their appreciation for the guidance, contribution, and support extended by them during their tenure. Mr. Harish Pande and Mr. Arun Kumar have ceased to be the Chairman and member of the Audit Committee and Nomination & Remuneration Committee and Stakeholders’ Relationship Committee, Risk Management Committee and CSR Committee respectively. The Company has appointed Mr. Sham Goel and Mr. Ashwani Kumar Sharma as Non-Executive-Independent Directors, who shall continue to be the Chairman and Member of the Audit Committee and Nomination & Remuneration Committee and Stakeholders’ Relationship Committee, Risk Management Committee and CSR Committee respectively.

Medicamen Biotech Ltd. has announced its unaudited financial results for the quarter ended on December 31, 2025. The company's revenue for the quarter stands at 4,349.07, with a net profit of 218.72. The company operates only in the pharmaceuticals formulations business segment. The financial results have been reviewed by the Audit Committee and approved by the Board of Directors.